Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
Shigehisa Kitano
National Cancer Center,
5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
Japan
Review Article
Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy
Author(s): Ayumu Ito, Shigehisa Kitano, Yongji Kim, Moeko Inoue, Masanori Fuse, Kohei Tada, and Kiyoshi YoshimuraAyumu Ito, Shigehisa Kitano, Yongji Kim, Moeko Inoue, Masanori Fuse, Kohei Tada, and Kiyoshi Yoshimura
Recent progress in cancer immunotherapy has been remarkable, especially the clinical development of immune checkpoint inhibitors, such as anti-CTLA-4 and anti-PD-1 antibodies. The success of these agents has revealed the importance of anti-tumor immune activities in curing cancers.
Cancer peptide vaccines constitute another approach to eliciting and boosting anti-tumor immune responses. While conventional cancer vaccines have had limited clinical efficacy, targeting mainly tumor-associated selfantigens, a novel approach is now being explored to target tumor-specific antigens generated from gene mutations occurring in tumor cells during neoplastic transformation. Theoretically, immune responses to these so-called “cancer neoantigens” are not attenuated by host central tolerance in the thymus and do not trigge.. View More»
DOI:
10.4172/2155-9899.1000322